Clinical Problem

250 million people worldwide suffer from osteoporosis, a bone disease characterized by a decrease in bone mass and a deterioration of the bone microarchitecture resulting in an increased fracture risk.

The presence of prevalent fractures doubles the risk for sustaining another fractures within the next 12 months.

For those patients at very high, imminent fracture risk, bone specialists are lacking a fast-acting treatment to locally strengthen fragile bones to prevent devastating fractures.

 

At flowbone, we address this treatment gap.

Bone_white_edited.jpg
 

Our Solution

flowbone provides a new generation of injectable bioactive gel  for a quick and subtle, local strengthening of fragile bones.

  • Unique Mode of Action

Once in place, the bioactive gel initiates the deposition of the body's own minerals and rapidly turns into strong, viable bone

  • Compliance with Bone Biology

No foreign material, no interference with bone vascularization and biomechanics

  • Minimal Invasiveness

The bioactive gel is injected with a cannula into bone regions at hight risk of fracture

20200331_174735.jpg

flowbone Ltd. was created in July 2020 as spin-off of the at the Laboratory of Biomechanical Orthopedics at the Swiss Federal Institute of Technology Lausanne (EPFL). It is headquartered in Renens (canton Vaud, Switzerland).

All our products are still under development and not available on the market.

At flowbone, we aim for a world where the elderly can enjoy a high level of independence and quality of life, free from the devastating impact of fragility fractures.

About Us
 
bg.jpg

Ulrike Kettenberger

CEO & Co-Founder

Valérie Malfroy Camine

COO & Co-Founder

Régis Gauderon

Chairman of the Board
& Co-Founder

Dominique Pioletti

Advisor
& Co-Founder

 
 
Our Supporters
 
bg.jpg
Interested?
Drop us a message and get the
latest news on our linkedin profile!

©2021 by flowbone Ltd.